Provectus Biopharmaceuticals is developing advanced therapies designed to target and destroy the deadliest cancers - melanoma, liver and breast - while minimizing side effects.

Research Grants show all

NIH1

Publications show all

Provectus Biopharmaceuticals has published 1 articles.

Patents show all

396Issued163Applications

Clinical Trials show all

6Phase 23Phase 11Phase 1/Phase 2

SEC Filings show all

8-K22410-Q31D1310-K9S-11

Contact Information


    SEC Form D Funding Events

    DateOfferedSoldType
    2014-10-15$15,000,000$0Equity, Option to Acquire
    2014-04-17$5,000,000$3,373,250Equity, Option to Acquire
    2013-09-26$16,000,000$7,798,037Equity, Option to Acquire
    2013-03-08$2,550,000$2,550,000Equity, Option to Acquire
    2012-11-19$5,000,000$2,034,675Equity, Option to Acquire
    2012-08-03$4,999,999$2,077,796Equity, Option to Acquire
    2012-03-22$2,499,999$499,999Equity, Option to Acquire
    2011-05-05$5,000,000$4,615,300Equity, Option to Acquire
    2010-05-13$1,000,000$200,000Equity
    2010-04-06$1,271,900$1,271,900Equity, Option to Acquire
    2010-03-26$10,363,327$7,613,327Equity, Option to Acquire
    2010-03-24$10,000,000$7,937,499Equity, Option to Acquire
    2007-06-06UnknownUnknownOther (Paper Filing)

    Key Executives

    • Peter R. Culpepper
      Executive Officer
    • Stuart Fuchs
      Director
    • Kelly M. McMasters
      Director
    • Eric A. Wachter
      Director
    • Craig H. Dees
      Executive Officer, Director
    • Timothy C. Scott
      Executive Officer, Director
    • Alfred E. Smith IV
      Director
    • Craig Dees
      Executive Officer, Director
    • H. Craig Dees
      Executive Officer, Director
    • Jan Koe
      Director
    • Eris A. Wachter
      Executive Officer
    • Tim Scott
      Executive Officer